Here is a detailed review of the clinical trial findings for albendazole and mebendazole, followed by the innovative delivery methods developed to overcome their pharmacological limitations.
1. Clinical Trial Results & Evidence for Albendazole (ABZ)
Pilot Study in Advanced Malignancies: A pilot study evaluated oral ABZ (10 mg/kg/day in two divided doses for 28 days) in seven patients with advanced hepatocellular carcinoma (HCC) or colorectal cancer (CRC) with hepatic metastases refractory to standard care.
Efficacy: ABZ significantly reduced serum tumor markers (carcinoembryonic antigen and α-fetoprotein) in two patients and stabilized them in three others.
Toxicity: Three patients developed acute neutropenia, which led to treatment cessation on day 19 in one study cohort.
Phase I Dose-Escalation Trial: A Phase I trial in 36 patients with refractory solid tumors escalated oral ABZ from 400 mg to 1,200 mg twice daily (2,400 mg/day total) in 21-day cycles (14 days on, 7 days off).
Outcome & Dosing: ABZ was well tolerated, establishing 1,200 mg twice daily as the recommended Phase II dose. Treatment decreased plasma vascular endothelial growth factor (VEGF) levels, with 16% of patients showing a tumor marker drop of at least 50%.
2. Clinical Trial Results & Case Studies for Mebendazole (MZ)
Clinical Case Reports:
Adrenocortical Carcinoma: A 48-year-old male treated with MZ monotherapy (100 mg twice daily) achieved initial regression followed by long-term disease stabilization without significant adverse effects.
Refractory Metastatic Colon Cancer: A 74-year-old male with oxaliplatin-induced neuropathy received 100 mg twice daily of MZ, experiencing near-complete remission of lung and lymph node metastases and partial remission in the liver without adverse reactions.
Clinical Trials:
Individualized High-Dose GI Study: A study of 11 patients with advanced gastrointestinal cancer tested dose-adjusted MBZ up to 4 g/day to target a serum concentration of 300 ng/mL. Five patients successfully reached the target serum level with no significant toxicity, proving high-dose MBZ is safe when monitored.
High-Grade Glioma (NCT01729260): A Phase I trial evaluated MBZ (500 mg three times daily in 28-day cycles) combined with temozolomide in newly diagnosed high-grade glioma patients, demonstrating good safety with no severe side effects.
Pediatric Glioma (NCT01837862): A Phase I/II trial tested MBZ (100 mg twice daily for 70 weeks) combined with carboplatin, temozolomide, and vincristine to evaluate progression-free and overall survival.
RepoMeb Trial (NCT03628079): A Phase II trial evaluating individualized serum-dosed MBZ in GI cancers was terminated due to a lack of clinical effect.
Combination & Adjuvant Trials: Ongoing trials include the METRICS study (NCT02201381), which tests a combination metabolic protocol (MBZ, metformin, doxycycline, and atorvastatin), and a Phase III trial (NCT03925662) evaluating MBZ as adjuvant therapy for colon cancer.
3. Innovative Delivery Methods & Bioavailability Strategies
The clinical translation of benzimidazole carbamates faces significant hurdles due to poor water solubility, low intestinal absorption, and extensive hepatic first-pass metabolism, which prevent oral doses from reaching effective therapeutic concentrations in systemic circulation. To overcome these pharmacokinetic barriers, several innovative delivery strategies are being explored:
Antibody-Drug Conjugates (ADCs): Benzimidazole carbamates can be conjugated to tumor-specific antibodies via cleavable or non-cleavable linkers. The antibody binds to specific cancer cell surface antigens, triggering endocytosis into early/late endosomes or lysosomes where linkers release the drug directly inside the cell. This localized release directly disrupts tumor microtubules while minimizing systemic toxicity.
Therapeutic Drug Monitoring (TDM) & Individualized Dosing: To compensate for unpredictable oral absorption, clinical protocols adjust patient dosages dynamically based on monitored serum concentrations (e.g., targeting ≥300 ng/mL with doses up to 4 g/day).
Nano-Formulations & Advanced Carriers: Research focuses on developing lipid nanoparticles and novel formulations engineered to improve gastrointestinal dissolution, shield drugs from rapid hepatic degradation, and boost systemic bioavailability.
Double Repositioning: Veterinary Antiparasitic to Human Anticancer
Sultana, T.; Jan, U.; Lee, J.I. Double Repositioning: Veterinary Antiparasitic to Human Anticancer. Int. J. Mol. Sci. 2022, 23, 4315. https://doi.org/10.3390/ijms23084315